Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus NIPRIDE RTU IN SODIUM CHLORIDE 0 9.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus NIPRIDE RTU IN SODIUM CHLORIDE 0 9.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs NIPRIDE RTU IN SODIUM CHLORIDE 0.9%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Sodium nitroprusside is a potent vasodilator that acts by releasing nitric oxide (NO), which activates guanylyl cyclase in vascular smooth muscle cells, increasing cGMP levels and leading to relaxation of both arterial and venous smooth muscle, thereby reducing peripheral resistance and cardiac preload.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Initial 0.3-0.5 mcg/kg/min IV continuous infusion, titrate by 0.5 mcg/kg/min every 3-5 minutes to desired effect; usual range 3-6 mcg/kg/min; maximum 10 mcg/kg/min.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Nitroprusside: ~2 minutes (converted to cyanide); cyanide: 1-2 hours (converted to thiocyanate); thiocyanate: 2.7-7 days (up to 14 days in renal impairment). Clinical context: Thiocyanate accumulation risk with prolonged use.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: 40-60% as thiocyanate at therapeutic doses; biliary: minimal; fecal: negligible.
Category C
Category A/B
Electrolyte
Electrolyte